Quality Control and Supply Chain Key Points for Core Raw Materials of Biodiagnostic Reagents

Raw material quality determines the performance baseline of diagnostic reagents.

The performance of biological diagnostic reagents is often largely determined at the raw material selection stage. The purity, activity, batch-to-batch consistency, and level of exogenous contaminants of core raw materials such as antigens, antibodies, enzymes, nucleic acid primers and probes, substrates, and buffers are directly related to detection sensitivity, specificity, and reproducibility. In the development of in vitro diagnostic products, even if subsequent process optimization is sufficient, batch-to-batch variability or trace contamination with nucleases or proteases in raw materials can easily lead to false positives, false negatives, or signal drift. Therefore, establishing a scientific raw material admission and evaluation mechanism is the prerequisite for ensuring stable product output.

Classification of key raw materials and common requirements

By application direction, commonly used raw materials for biological diagnostic reagents can be broadly divided into immunodiagnostic raw materials and molecular diagnostic raw materials. In immunodiagnostics, recombinant antigens, monoclonal antibodies, polyclonal antibodies, and enzyme-labeled secondary antibodies are relatively common. For antibody raw materials, attention is generally paid to affinity, specificity, cross-reactivity, batch-to-batch variation, and storage stability; for antigen raw materials, purity, degree of native conformation retention, and integrity of key epitopes need to be examined. In molecular diagnostics, Taq DNA polymerase, reverse transcriptase, dNTPs, primer probes, and nuclease-free water are basic components. Related raw materials are generally required to be free of nucleases and exogenous nucleic acid contamination, have clearly defined enzyme activity units, and remain stable in amplification efficiency and sensitivity across different batches.

Antibodies/antigens: focus on affinity, cross-reactivity, batch-to-batch consistency, and stability.

Enzymes: focus on specific activity, absence of nuclease/protease contamination, and freeze-thaw stability.

Primer probes: focus on purity, sequence correctness, and modification labeling efficiency.

Buffers and substrates: focus on pH buffering capacity, residual metal ions, and photosensitive and heat-sensitive impurities.

Quality control and batch traceability

Raw material quality control should not stop at the incoming inspection stage, but should extend to supplier audits, small-sample verification, pilot-scale scale-up, and continuous monitoring. Common practices include establishing raw material quality standards, retention sample systems, and stability study plans. For key raw materials, suppliers are usually required to provide a certificate of analysis (CoA), accompanied by test data such as purity, activity, endotoxin, and bioburden. Internally, companies can combine accelerated stability testing and real-time stability data to determine raw material shelf life and retest dates. In terms of batch traceability, it is recommended to record raw material lot numbers, arrival dates, inspection results, product batches used, and customer feedback to form a traceable chain. Once performance drift occurs, problematic raw materials can be quickly identified and a risk assessment initiated.

Cold-chain storage, transportation, and inventory management

Most biological diagnostic reagent raw materials are sensitive to temperature, humidity, and light. Enzymes, antibodies, and premixed solutions often need to be stored at -20°C or lower, while some lyophilized products can be stored at 2-8°C. Warehousing and transportation conditions should have continuous temperature monitoring to avoid repeated freeze-thaw cycles. In practice, companies can classify storage levels based on raw material stability data, set up different areas such as refrigerated, frozen, and ultra-low temperature, and equip them with temperature alarm systems. Inventory management should adopt the first-in, first-out principle, and raw materials approaching their retest date should be inspected promptly or downgraded for use. For raw materials requiring cold-chain transportation, transportation validation data should be confirmed to ensure that temperature deviations during transportation will not affect subsequent product performance.

Industry trends and compliance awareness

As regulation of in vitro diagnostic reagents becomes stricter and clinical requirements for the accuracy of test results increase, standardization, localization, and sustainable supply at the raw material end are receiving increasing attention. Raw material suppliers with comprehensive quality systems and stable processes are becoming the preferred choice for long-term cooperation by diagnostic companies. At the same time, companies should proactively pay attention to relevant regulations and technical guidelines, and establish internal processes for change management, supplier reassessment, and alternative raw material verification. Only by controlling quality at the source can batch-to-batch variation be reduced and the reliability of biological diagnostic reagent products throughout their life cycle be improved.